July 13, 2018 – By Ashley Bratcher
Broadfin Capital Llc increased Gw Pharmaceuticals Plc (GWPH) stake by 42.38% reported in 2018Q1 SEC filing. Broadfin Capital Llc acquired 52,100 shares as Gw Pharmaceuticals Plc (GWPH)’s stock rose 36.14%. The Broadfin Capital Llc holds 175,030 shares with $19.72M value, up from 122,930 last quarter. Gw Pharmaceuticals Plc now has $4.28B valuation. The stock increased 1.37% or $2.06 during the last trading session, reaching $151.89. About 205,773 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 49.14% since July 13, 2017 and is uptrending. It has outperformed by 36.57% the S&P500. Some Historical GWPH News: 16/03/2018 – HQGE Unveils Extensive Cannabidiol (CBD Oil) Database, Teams with Hemp, Inc. to Produce and Distribute High-Quality Customizable CBD Extractions; 19/04/2018 – GW Pharma Wins Unanimous Recommendation From FDA Advisory Committee For Cannabis-derived Drug — MarketWatch; 16/05/2018 – GW Pharmaceuticals: Epidiolex Reduced Monthly Frequency of Drop Seizures; 19/04/2018 – ADVISERS VOTE 13-0 GW PHARMA DRUG’S BENEFITS OUTWEIGH RISKS; 19/04/2018 – GWPH, ZYNE: Panel votes 13 to 0 that $GWPH’s Epidiolex (cannabidiol) has a favorable risk/benefit profile. – ! $GWPH $ZYNE; 19/04/2018 – GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now $GWPH; 19/04/2018 – The medication, which is manufactured by GW Pharmaceuticals, is used in the treatment of seizures associated with childhood epilepsy; 06/04/2018 – lsodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals; 17/04/2018 – GW PHARMA’S CANNABIDIOL DRUG GETS FAVORABLE FDA STAFF REVIEW; 24/05/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Cannabidiol Isolate to Sundial
Wealthfront Inc increased Southern Co Com (SO) stake by 20.8% reported in 2018Q1 SEC filing. Wealthfront Inc acquired 12,192 shares as Southern Co Com (SO)’s stock rose 1.11%. The Wealthfront Inc holds 70,800 shares with $3.16 million value, up from 58,608 last quarter. Southern Co Com now has $48.35 billion valuation. The stock decreased 0.40% or $0.19 during the last trading session, reaching $47.79. About 1.76M shares traded. The Southern Company (NYSE:SO) has declined 11.84% since July 13, 2017 and is downtrending. It has underperformed by 24.41% the S&P500. Some Historical SO News: 21/05/2018 – SO: NOW SEES NEED TO RAISE $3 BLN OVER FIVE YEARS; 07/05/2018 – SOUTHERN CUTS HATCH 2 REACTOR TO 49% POWER FROM 100%: NRC; 09/04/2018 – Georgia Power to add 177 MW of solar resources for C&I REDI program; 17/04/2018 – SOUTHERN CO – ANDREW W. EVANS WILL BECOME EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER OF SOUTHERN COMPANY; 21/05/2018 – NextEra to Buy Florida Utility From Southern for $5.1 Billion; 11/04/2018 – Alabama Power Dividends Declared; 06/03/2018 – Southern Co.: Georgia Power Customers to Receive $1.2 B in Benefits From Tax Overhau; 21/05/2018 – NextEra to Buy Southern Co. Florida Utilities for $5.1 Billion; 29/05/2018 – SOUTHERN CO – ONCE OPERATIONAL, ALL ATTRIBUTES GENERATED BY FACILITY WILL BE SOLD UNDER A 20-YR POWER PURCHASE AGREEMENT TO AECC; 07/05/2018 – GEORGIA POWER – EACH OFFER WILL EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, ON JUNE 4, 2018, UNLESS EXTENDED OR EARLIER TERMINATED
Among 5 analysts covering GW Pharma (NASDAQ:GWPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharma had 9 analyst reports since January 23, 2018 according to SRatingsIntel. The company was maintained on Tuesday, January 23 by Leerink Swann. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, February 5. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Tuesday, April 17 by Cantor Fitzgerald. Bank of America maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Tuesday, June 26. Bank of America has “Buy” rating and $200 target. The rating was maintained by Cowen & Co with “Buy” on Wednesday, April 18. The firm has “Outperform” rating given on Tuesday, February 6 by Leerink Swann. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, June 25. The rating was maintained by Bank of America with “Buy” on Tuesday, February 6. The firm earned “Buy” rating on Tuesday, June 26 by Goldman Sachs.
More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Seekingalpha.com which released: “GW Pharmaceuticals: What The Recent Epidiolex Approval Foretells” on July 13, 2018, also Nasdaq.com with their article: “Here’s Why Marijuana Stock GW Pharmaceuticals Fell 13.3% in June” published on July 13, 2018, Seekingalpha.com published: “Issues To Watch Out For In GW Pharma” on July 09, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Nasdaq.com and their article: “Why Zogenix Inc. Is Soaring Today” published on July 12, 2018 as well as Benzinga.com‘s news article titled: “GW Pharma’s Epidiolex Becomes First Cannabis-Based FDA-Approved Drug” with publication date: June 26, 2018.
Broadfin Capital Llc decreased Biodelivery Sciences Intl In (NASDAQ:BDSI) stake by 355,300 shares to 4.28 million valued at $9.63 million in 2018Q1. It also reduced Iovance Biotherapeutics Inc stake by 1.43M shares and now owns 912,987 shares. Veracyte Inc (NASDAQ:VCYT) was reduced too.
Wealthfront Inc decreased Ishares Tr National Mun Etf (MUB) stake by 1.06M shares to 2.11M valued at $229.31M in 2018Q1. It also reduced Facebook Inc Cl A (NASDAQ:FB) stake by 47,755 shares and now owns 197,291 shares. Twitter Inc Com (NYSE:TWTR) was reduced too.
Another recent and important The Southern Company (NYSE:SO) news was published by Seekingalpha.com which published an article titled: “Watchlist July 2018” on July 12, 2018.
Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.21, from 1.1 in 2017Q4. It is negative, as 76 investors sold SO shares while 359 reduced holdings. 75 funds opened positions while 310 raised stakes. 558.65 million shares or 1.91% more from 548.17 million shares in 2017Q4 were reported. Fdx Advsrs has 112,785 shares for 0.15% of their portfolio. Vident Invest Advisory Limited accumulated 0.04% or 23,366 shares. Regentatlantic Lc holds 4,585 shares or 0.02% of its portfolio. Moreover, Hl Serv Ltd Liability Co has 0.12% invested in The Southern Company (NYSE:SO). Td Asset Management invested in 0.05% or 701,071 shares. Arcadia Management Corp Mi owns 343 shares. Jefferies Group Incorporated Ltd Liability Company holds 25,417 shares or 0.01% of its portfolio. Haverford Tru holds 0.01% or 12,307 shares. 57,239 are held by Etrade Cap Mngmt Limited Com. Hayek Kallen Mgmt stated it has 1.04% in The Southern Company (NYSE:SO). Hudson Valley Invest Inc Adv holds 0.09% of its portfolio in The Southern Company (NYSE:SO) for 7,674 shares. Moreover, South Texas Money Mgmt Limited has 0.01% invested in The Southern Company (NYSE:SO). Benin Mgmt Corporation accumulated 9,068 shares or 0.18% of the stock. Employees Retirement System Of Texas has 0.03% invested in The Southern Company (NYSE:SO) for 42,000 shares. Paloma Partners Mngmt has 0.01% invested in The Southern Company (NYSE:SO) for 17,543 shares.
Among 9 analysts covering Southern Co (NYSE:SO), 2 have Buy rating, 2 Sell and 5 Hold. Therefore 22% are positive. Southern Co had 25 analyst reports since January 16, 2018 according to SRatingsIntel. The rating was maintained by SunTrust on Monday, February 5 with “Hold”. The firm has “Underweight” rating given on Tuesday, April 10 by JP Morgan. Credit Suisse maintained The Southern Company (NYSE:SO) rating on Tuesday, February 27. Credit Suisse has “Underperform” rating and $45 target. The firm has “Neutral” rating given on Tuesday, January 23 by Mizuho. The company was maintained on Monday, March 19 by SunTrust. The firm earned “Underweight” rating on Monday, April 16 by Morgan Stanley. As per Monday, April 23, the company rating was maintained by SunTrust. As per Friday, February 23, the company rating was maintained by SunTrust. SunTrust maintained The Southern Company (NYSE:SO) on Monday, April 9 with “Hold” rating. The firm earned “Buy” rating on Tuesday, May 22 by Deutsche Bank.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.